ORKA
Oruka Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth — ·
share flow — ·
net new positions +20.0%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 98 | +25 | 38.87M | $3.69B | +30 | −5 |
| Q1 2026 | 76 | +12 | 25.47M | $1.25B | +17 | −5 |
| Q4 2025 | 63 | +1 | 24.86M | $753.58M | +1 | — |
| Q3 2025 | 15 | +1 | 17.63M | $338.97M | +3 | −2 |
| Q2 2025 | 11 | 0 | 11.37M | $127.46M | +1 | −1 |
| Q1 2025 | 8 | +1 | 1.39M | $14.29M | +2 | −1 |
| Q4 2024 | 7 | +1 | 2.25M | $43.63M | +1 | — |
| Q3 2024 | 5 | +5 | 1.06M | $25.93M | +5 | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management ✦ | 482.33K | New | $11.82M | 0.0% | New | 1 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 279.65K | New | $6.86M | 0.0% | New | 1 | SEC ↗ |
| 3 | T. Rowe Price ✦ | 279.65K | New | $6.86M | 0.0% | New | 1 | SEC ↗ |
| 4 | Adage Capital Partners ✦ | 200.00K | New | $4.90M | 0.0% | New | 1 | SEC ↗ |
| 5 | Wellington Management ✦ | 82.14K | New | $2.01M | 0.0% | New | 1 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passive) | 13.98K | New | $342,781 | 0.0% | New | 1 | SEC ↗ |
| 7 | Geode Capital Management ✦ (passive) | 13.98K | New | $342,781 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Point72 Asset Management | $11.82M | 0.0% |
| T. Rowe Price | $6.86M | 0.0% |
| T. Rowe Price | $6.86M | 0.0% |
| Adage Capital Partners | $4.90M | 0.0% |
| Wellington Management | $2.01M | 0.0% |
| Geode Capital Management | $342,781 | 0.0% |
| Geode Capital Management | $342,781 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 183 holders, 52.32M shares, $2.54B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 900 sh · $98,687
Officer · 300 sh · $33,155
Officer · 3.32K sh · $371,886
Officer · 2.48K sh · $279,154
Officer · 3.63K sh · $384,963
Officer · 10.43K sh · $1.12M
Officer · 14.70K sh · $1.59M
Officer · 10.20K sh · $1.11M
Officer · 9.19K sh · $1.01M
Officer · 3.85K sh · $427,547
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
19.5% of class · View original SEC filing ↗